Danaher (DHR) expects FY25 adj. EPS at the upper-end of the previously announced USD 7.70-7.80 guidance range

• Q4 revenue growth seen at the high-end of the announced range.
• CEO "We were especially pleased with continued strength in Bioprocessing and better-than-expected Life Sciences and Diagnostics revenue in the fourth quarter."

Danaher is providing guidance for FY25 adjusted EPS that aligns with the high end of their previous range, suggesting solid operational performance. The CEO's remarks about strengths in key areas like Bioprocessing and Life Sciences highlight robust demand, which could positively influence investor sentiment and support the stock price. Overall, this update signals confidence in growth prospects and reaffirms Danaher's position in the market.